CMS accelerates Medicare price negotiations for drugs with hyaluronidase, impacting biologic drug pricing and pharmaceutical companies like Halozyme Therapeutics and Johnson & Johnson.
President Trump signs an executive order setting a 30-day deadline for drugmakers to lower prescription drug prices in the U.S. or face new federal limits tied to international prices.
President Trump announces an executive order aiming to reduce U.S. prescription drug prices by 30-80% through a 'Most Favored Nation' pricing policy affecting healthcare and insurance markets.
The Trump administration plans to reintroduce a 'most favored nation' drug pricing model for Medicare, aiming to align U.S. drug prices with lower international rates. This strategy faces industry opposition but could complement existing Medicare drug price negotiations to reduce costs.
Pharmaceutical companies increased consumer-directed drug advertising by nearly 30% in early 2025, leveraging tax deductions that affect prescription drug prices, according to AHIP and CSRxP analyses.
CMS's 2026 Final Rule implements the Medicare Drug Price Negotiation Program with the Medicare Transaction Facilitator, affecting Part D drug pricing and pharmacy reimbursement processes.
Insights on recent shifts in U.S. health policy: autism research, drug pricing reforms, HHS operational cuts, abortion access, and legal challenges to insurance preventive care coverage.
Explore how Medicare Part D and C plans cover Jardiance for heart failure and type 2 diabetes, including costs, formularies, and pricing reforms under the Inflation Reduction Act.
Medicare beneficiaries face higher costs as Part D plans shift from fixed co-pays to coinsurance for expensive Tier 3 drugs, raising out-of-pocket expenses significantly.
Summary of Trump's executive order directing HHS to reduce prescription drug costs, focusing on Medicare reimbursement for 340B drugs, IRA drug pricing provisions, and CMS premium stabilization efforts.
